Cargando…
Hepatitis B virus reactivation or reinfection in a FEM-PrEP participant: a case report
INTRODUCTION: The FEM-PrEP trial was a pre-exposure prophylaxis clinical trial to test the safety and efficacy of Truvada (tenofovir disoproxil fumarate and emtricitabine) in the prevention of human immunodeficiency virus infection. Because Truvada can suppress hepatitis B virus replication, and wit...
Autores principales: | Malahleha, Mookho, Ahmed, Khatija, Deese, Jennifer, Nanda, Kavita, van Damme, Lut, De Baetselier, Irith, Burnett, Rosemary J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4586016/ https://www.ncbi.nlm.nih.gov/pubmed/26411737 http://dx.doi.org/10.1186/s13256-015-0679-4 |
Ejemplares similares
-
Facilitators of Adherence to the Study Pill in the FEM-PrEP Clinical Trial
por: Corneli, Amy, et al.
Publicado: (2015) -
FEM-PrEP: Adherence Patterns and Factors Associated With Adherence to a Daily Oral Study Product for Pre-exposure Prophylaxis
por: Corneli, Amy L., et al.
Publicado: (2014) -
Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials
por: Agot, Kawango, et al.
Publicado: (2014) -
Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial()()
por: Nanda, Kavita, et al.
Publicado: (2016) -
The Sexual Risk Context among the FEM-PrEP Study Population in Bondo, Kenya and Pretoria, South Africa
por: Headley, Jennifer, et al.
Publicado: (2014)